中国医药外包服务要取得长足发展,改善政策环境已是当务之急受金融危机影响较小《中国投资》:一种观点认为,由于医药研发外包自身的特点,使它可能成为金融危机时期的资本避风港。对此您怎么看?吴玫涵:如果从刚性需求角度来讲,金融危机对生物医药行业的需求影响不大,整个行业不会出现剧烈的变动,但是也不能独善其身,影响可能会滞后 China’s pharmaceutical outsourcing service needs to make great strides and improve its policy environment. It is imperative that it be less affected by the financial crisis. “China’s Investment”: One view is that due to the characteristics of pharmaceutical R & D outsourcing, it may become a capital safe-haven during the financial crisis. What do you think about it? Wu Meihan: If from a rigid demand perspective, the financial crisis has little effect on the demand of the biopharmaceutical industry. There will be no drastic changes in the industry as a whole. However, the impact on the industry may lag behind